Abstract | BACKGROUND: METHODS: RESULTS: In the PSA, the rate of complete remission or complete remission with partial hematologic recovery was 36% for blinatumomab and 25% for SOC, and this resulted in an odds ratio of 1.54 (95% confidence interval [CI], 0.61-3.89) or 1.70 (95% credible interval [CrI], 0.94-2.94) with Bayesian data augmentation. Overall survival favored blinatumomab over SOC, with a hazard ratio of 0.81 (95% CI, 0.57-1.14) or 0.77 (95% CrI, 0.61-0.96) with Bayesian data augmentation. CONCLUSIONS: These results further support blinatumomab as a treatment option for patients with r/r Ph+ ALL.
|
Authors | Alessandro Rambaldi, Josep-Maria Ribera, Hagop M Kantarjian, Hervé Dombret, Oliver G Ottmann, Anthony S Stein, Catherine A Tuglus, Xiaoyue Zhao, Christopher Kim, Giovanni Martinelli |
Journal | Cancer
(Cancer)
Vol. 126
Issue 2
Pg. 304-310
(01 15 2020)
ISSN: 1097-0142 [Electronic] United States |
PMID | 31626339
(Publication Type: Clinical Trial, Phase II, Comparative Study, Journal Article, Multicenter Study, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Copyright | © 2019 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society. |
Chemical References |
- Antibodies, Bispecific
- blinatumomab
|
Topics |
- Adolescent
- Adult
- Antibodies, Bispecific
(pharmacology, therapeutic use)
- Antineoplastic Combined Chemotherapy Protocols
(pharmacology, therapeutic use)
- Drug Resistance, Neoplasm
- Female
- Follow-Up Studies
- Hematopoietic Stem Cell Transplantation
- Humans
- Male
- Middle Aged
- Neoplasm Recurrence, Local
(drug therapy, genetics, mortality, pathology)
- Philadelphia Chromosome
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
(genetics, mortality, pathology, therapy)
- Propensity Score
- Salvage Therapy
(methods)
- Standard of Care
- Transplantation, Homologous
- Treatment Outcome
- Young Adult
|